Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 6—June 2020
Research

Emergence of New Non–Clonal Group 258 High-Risk Clones among Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae Isolates, France

Rémy A. Bonnin, Agnès B. Jousset, Adriana Chiarelli, Cécile Emeraud, Philippe Glaser, Thierry Naas, and Laurent DortetComments to Author 
Author affiliations: Institut Pasteur–Assistance Publique/Hôpitaux de Paris–University Paris Sud, Paris, France (R.A. Bonnin, A.B. Jousset, A. Chiarelli, C. Emeraud, T. Naas, L. Dortet); Faculty of Medicine University Paris-Sud, University Paris–Saclay, Le Kremlin-Bicêtre, France (R.A. Bonnin, A.B. Jousset, C. Emeraud, T. Naas, L. Dortet); National Reference Center for Antibiotic Resistance: Carbapenemase Producing Enterobacteriaceae, Le Kremlin-Bicêtre, (R.A. Bonnin, A.B. Jousset, C. Emeraud, T. Naas, L. Dortet); Assistance Publique/Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre (A.B. Jousset, C. Emeraud, T. Naas, L. Dortet)

Main Article

Figure 1

Susceptibility testing of Klebsiella pneumoniae carbapenemase–producing K. pneumoniae isolates, France, 2018. A) Antimicrobial susceptibility to carbapenems tested by using the disc diffusion method and interpreted according to European Committee on Antimicrobial Susceptibility Testing guidelines (http://www.eucast.org). B) Susceptibility to ceftazidime or ceftazidime/avibactam combination. C) MICs for colistin as determined by broth microdilution. D) Percentage of susceptibility to other antibi

Figure 1. Susceptibility testing of Klebsiella pneumoniae carbapenemase–producing K. pneumoniae isolates, France, 2018. A) Antimicrobial susceptibility to carbapenems tested by using the disc diffusion method and interpreted according to European Committee on Antimicrobial Susceptibility Testing guidelines (http://www.eucast.org). B) Susceptibility to ceftazidime or ceftazidime/avibactam combination. C) MICs for colistin as determined by broth microdilution. D) Percentage of susceptibility to other antibiotic families. Where percentage of resistance is <100%, percentage of susceptible isolates is indicated. AMC, amoxicillin/clavulanate; AMK, amikacin; AMX, amoxicillin; CIP, ciprofloxacin; CHL, chloramphenicol; C/T, ceftolozane/tazobactam; CTX, cefotaxime; FEP, cefepime; GEN, gentamicin; I, intermediate; LEV, levofloxacin; MEC, mecillinam; NET, netilmicin; NIT, nitrofurane; PIP, piperacillin; PTZ, piperacillin/tazobactam; R, resistant; S, susceptible; TCC, ticarcillin/clavulanate; TEM, temocillin; TGC, tigecycline; TIC, ticarcillin.

Main Article

Page created: May 18, 2020
Page updated: May 18, 2020
Page reviewed: May 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external